Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
Identifieur interne : 000761 ( Main/Exploration ); précédent : 000760; suivant : 000762Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
Auteurs : Ernesto Martínez-Martínez [France] ; Laurent Calvier [France] ; Amaya Fernández-Celis [France] ; Elodie Rousseau [France] ; Raquel Jurado-L Pez [France] ; Luciana V. Rossoni [France] ; Frederic Jaisser [France] ; Faiez Zannad [France] ; Patrick Rossignol [France] ; Victoria Cachofeiro [France] ; Natalia L Pez-Andrés [Espagne]Source :
- Hypertension [ 1524-4563 ] ; 2015.
Descripteurs français
- KwdFr :
- Animaux, Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique), Cellules cultivées, Fibroblastes (), Fibroblastes (anatomopathologie), Fibrose (anatomopathologie), Fibrose (étiologie), Galectine -3 (antagonistes et inhibiteurs), Galectine -3 (biosynthèse), Humains, Hyperaldostéronisme (), Hyperaldostéronisme (métabolisme), Hyperaldostéronisme (traitement médicamenteux), Hypertension artérielle (), Hypertension artérielle (métabolisme), Hypertension artérielle (traitement médicamenteux), Modèles animaux de maladie humaine, Myocardite (), Myocardite (anatomopathologie), Myocardite (étiologie), Mâle, Rat Wistar, Rats, Rats de lignée WKY, Souris, Souris de lignée C57BL, Souris knockout, Spironolactone (usage thérapeutique).
- MESH :
- anatomopathologie : Fibroblastes, Fibrose, Myocardite.
- antagonistes et inhibiteurs : Galectine -3.
- biosynthèse : Galectine -3.
- métabolisme : Hyperaldostéronisme, Hypertension artérielle.
- traitement médicamenteux : Hyperaldostéronisme, Hypertension artérielle.
- usage thérapeutique : Antagonistes des récepteurs des minéralocorticoïdes, Spironolactone.
- étiologie : Fibrose, Myocardite.
- Animaux, Cellules cultivées, Fibroblastes, Humains, Hyperaldostéronisme, Hypertension artérielle, Modèles animaux de maladie humaine, Myocardite, Mâle, Rat Wistar, Rats, Rats de lignée WKY, Souris, Souris de lignée C57BL, Souris knockout.
English descriptors
- KwdEn :
- Animals, Cells, Cultured, Disease Models, Animal, Fibroblasts (drug effects), Fibroblasts (pathology), Fibrosis (etiology), Fibrosis (pathology), Galectin 3 (antagonists & inhibitors), Galectin 3 (biosynthesis), Humans, Hyperaldosteronism (complications), Hyperaldosteronism (drug therapy), Hyperaldosteronism (metabolism), Hypertension (complications), Hypertension (drug therapy), Hypertension (metabolism), Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mineralocorticoid Receptor Antagonists (therapeutic use), Myocarditis (etiology), Myocarditis (pathology), Myocarditis (prevention & control), Rats, Rats, Inbred WKY, Rats, Wistar, Spironolactone (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Galectin 3.
- chemical , biosynthesis : Galectin 3.
- complications : Hyperaldosteronism, Hypertension.
- drug effects : Fibroblasts.
- drug therapy : Hyperaldosteronism, Hypertension.
- etiology : Fibrosis, Myocarditis.
- metabolism : Hyperaldosteronism, Hypertension.
- pathology : Fibroblasts, Fibrosis, Myocarditis.
- prevention & control : Myocarditis.
- chemical , therapeutic use : Mineralocorticoid Receptor Antagonists, Spironolactone.
- Animals, Cells, Cultured, Disease Models, Animal, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Rats, Rats, Inbred WKY, Rats, Wistar.
Abstract
Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise mechanisms are still unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potential role in cardiac damage associated with hypertension. Aldosterone-salt-treated rats presented hypertension, cardiac inflammation, and fibrosis that were prevented by the pharmacological inhibition of Gal-3 with modified citrus pectin. Cardiac inflammation and fibrosis presented in spontaneously hypertensive rats were prevented by modified citrus pectin treatment, whereas Gal-3 blockade did not modify blood pressure levels. In the absence of blood pressure modifications, Gal-3 knockout mice were resistant to aldosterone-induced cardiac inflammation. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via its mineralocorticoid receptor. Gal-3 and aldosterone enhanced proinflammatory and profibrotic markers, as well as metalloproteinase activities in human cardiac fibroblasts, effects that were not observed in Gal-3-silenced cells treated with aldosterone. In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels. These data suggest that Gal-3 could be a new molecular mechanism linking cardiac inflammation and fibrosis in situations with high-aldosterone levels, such as hypertension.
DOI: 10.1161/HYPERTENSIONAHA.115.05876
PubMed: 26238446
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000044
- to stream PubMed, to step Curation: 000044
- to stream PubMed, to step Checkpoint: 000052
- to stream Ncbi, to step Merge: 000200
- to stream Ncbi, to step Curation: 000193
- to stream Ncbi, to step Checkpoint: 000193
- to stream Main, to step Merge: 000750
- to stream Main, to step Curation: 000761
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.</title><author><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Calvier, Laurent" sort="Calvier, Laurent" uniqKey="Calvier L" first="Laurent" last="Calvier">Laurent Calvier</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Fernandez Celis, Amaya" sort="Fernandez Celis, Amaya" uniqKey="Fernandez Celis A" first="Amaya" last="Fernández-Celis">Amaya Fernández-Celis</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rousseau, Elodie" sort="Rousseau, Elodie" uniqKey="Rousseau E" first="Elodie" last="Rousseau">Elodie Rousseau</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Jurado L Pez, Raquel" sort="Jurado L Pez, Raquel" uniqKey="Jurado L Pez R" first="Raquel" last="Jurado-L Pez">Raquel Jurado-L Pez</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rossoni, Luciana V" sort="Rossoni, Luciana V" uniqKey="Rossoni L" first="Luciana V" last="Rossoni">Luciana V. Rossoni</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frederic" last="Jaisser">Frederic Jaisser</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Cachofeiro, Victoria" sort="Cachofeiro, Victoria" uniqKey="Cachofeiro V" first="Victoria" last="Cachofeiro">Victoria Cachofeiro</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name><affiliation wicri:level="1"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.). natalia.lopez.andres@navarra.es.</nlm:affiliation><country wicri:rule="url">Espagne</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26238446</idno><idno type="pmid">26238446</idno><idno type="doi">10.1161/HYPERTENSIONAHA.115.05876</idno><idno type="wicri:Area/PubMed/Corpus">000044</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000044</idno><idno type="wicri:Area/PubMed/Curation">000044</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000044</idno><idno type="wicri:Area/PubMed/Checkpoint">000052</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000052</idno><idno type="wicri:Area/Ncbi/Merge">000200</idno><idno type="wicri:Area/Ncbi/Curation">000193</idno><idno type="wicri:Area/Ncbi/Checkpoint">000193</idno><idno type="wicri:Area/Main/Merge">000750</idno><idno type="wicri:Area/Main/Curation">000761</idno><idno type="wicri:Area/Main/Exploration">000761</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.</title><author><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Calvier, Laurent" sort="Calvier, Laurent" uniqKey="Calvier L" first="Laurent" last="Calvier">Laurent Calvier</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Fernandez Celis, Amaya" sort="Fernandez Celis, Amaya" uniqKey="Fernandez Celis A" first="Amaya" last="Fernández-Celis">Amaya Fernández-Celis</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rousseau, Elodie" sort="Rousseau, Elodie" uniqKey="Rousseau E" first="Elodie" last="Rousseau">Elodie Rousseau</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Jurado L Pez, Raquel" sort="Jurado L Pez, Raquel" uniqKey="Jurado L Pez R" first="Raquel" last="Jurado-L Pez">Raquel Jurado-L Pez</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rossoni, Luciana V" sort="Rossoni, Luciana V" uniqKey="Rossoni L" first="Luciana V" last="Rossoni">Luciana V. Rossoni</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frederic" last="Jaisser">Frederic Jaisser</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="Cachofeiro, Victoria" sort="Cachofeiro, Victoria" uniqKey="Cachofeiro V" first="Victoria" last="Cachofeiro">Victoria Cachofeiro</name><affiliation wicri:level="4"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.).</nlm:affiliation><orgName type="university">Université de Lorraine</orgName><country>France</country><placeName><settlement type="city">Nancy</settlement><settlement type="city">Metz</settlement><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region></placeName></affiliation></author><author><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name><affiliation wicri:level="1"><nlm:affiliation>From the Cardiovascular Translational Research, Navarrabiomed (Fundación Miguel Servet), Pamplona, Spain (E.M.-M., A.F.-C., N.L.-A.); INSERM, Centre d'Investigations Cliniques- Plurithématique 1433, UMR 1116 Université de Lorraine, CHRU de Nancy, and INI-CRCT (Cardiovascular and Renal Clinical Trialists), French-Clinical Research Infrastructure Network (F-CRIN), Nancy, France (L.C., E.R., F.J., F.Z., P.R., N.L.-A.); Department of Physiology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain (R.J.-L., V.C.); Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil (L.V.R.); and INSERM UMR 872 Team 1, Centre de Recherche des Cordeliers, University Pierre and Marie Curie, Paris, France (F.J.). natalia.lopez.andres@navarra.es.</nlm:affiliation><country wicri:rule="url">Espagne</country></affiliation></author></analytic><series><title level="j">Hypertension</title><idno type="eISSN">1524-4563</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Disease Models, Animal</term><term>Fibroblasts (drug effects)</term><term>Fibroblasts (pathology)</term><term>Fibrosis (etiology)</term><term>Fibrosis (pathology)</term><term>Galectin 3 (antagonists & inhibitors)</term><term>Galectin 3 (biosynthesis)</term><term>Humans</term><term>Hyperaldosteronism (complications)</term><term>Hyperaldosteronism (drug therapy)</term><term>Hyperaldosteronism (metabolism)</term><term>Hypertension (complications)</term><term>Hypertension (drug therapy)</term><term>Hypertension (metabolism)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term><term>Mineralocorticoid Receptor Antagonists (therapeutic use)</term><term>Myocarditis (etiology)</term><term>Myocarditis (pathology)</term><term>Myocarditis (prevention & control)</term><term>Rats</term><term>Rats, Inbred WKY</term><term>Rats, Wistar</term><term>Spironolactone (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antagonistes des récepteurs des minéralocorticoïdes (usage thérapeutique)</term><term>Cellules cultivées</term><term>Fibroblastes ()</term><term>Fibroblastes (anatomopathologie)</term><term>Fibrose (anatomopathologie)</term><term>Fibrose (étiologie)</term><term>Galectine -3 (antagonistes et inhibiteurs)</term><term>Galectine -3 (biosynthèse)</term><term>Humains</term><term>Hyperaldostéronisme ()</term><term>Hyperaldostéronisme (métabolisme)</term><term>Hyperaldostéronisme (traitement médicamenteux)</term><term>Hypertension artérielle ()</term><term>Hypertension artérielle (métabolisme)</term><term>Hypertension artérielle (traitement médicamenteux)</term><term>Modèles animaux de maladie humaine</term><term>Myocardite ()</term><term>Myocardite (anatomopathologie)</term><term>Myocardite (étiologie)</term><term>Mâle</term><term>Rat Wistar</term><term>Rats</term><term>Rats de lignée WKY</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris knockout</term><term>Spironolactone (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Galectin 3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Galectin 3</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Fibroblastes</term><term>Fibrose</term><term>Myocardite</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Galectine -3</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Galectine -3</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Hyperaldosteronism</term><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Fibroblasts</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hyperaldosteronism</term><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Fibrosis</term><term>Myocarditis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Hyperaldosteronism</term><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hyperaldostéronisme</term><term>Hypertension artérielle</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Fibroblasts</term><term>Fibrosis</term><term>Myocarditis</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Myocarditis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Mineralocorticoid Receptor Antagonists</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hyperaldostéronisme</term><term>Hypertension artérielle</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs des minéralocorticoïdes</term><term>Spironolactone</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fibrose</term><term>Myocardite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Disease Models, Animal</term><term>Humans</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Mice, Knockout</term><term>Rats</term><term>Rats, Inbred WKY</term><term>Rats, Wistar</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules cultivées</term><term>Fibroblastes</term><term>Humains</term><term>Hyperaldostéronisme</term><term>Hypertension artérielle</term><term>Modèles animaux de maladie humaine</term><term>Myocardite</term><term>Mâle</term><term>Rat Wistar</term><term>Rats</term><term>Rats de lignée WKY</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Souris knockout</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hypertensive cardiac remodeling is accompanied by molecular inflammation and fibrosis, 2 mechanisms that finally affect cardiac function. At cardiac level, aldosterone promotes inflammation and fibrosis, although the precise mechanisms are still unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is associated with inflammation and fibrosis in the cardiovascular system. We herein investigated whether Gal-3 inhibition could block aldosterone-induced cardiac inflammation and fibrosis and its potential role in cardiac damage associated with hypertension. Aldosterone-salt-treated rats presented hypertension, cardiac inflammation, and fibrosis that were prevented by the pharmacological inhibition of Gal-3 with modified citrus pectin. Cardiac inflammation and fibrosis presented in spontaneously hypertensive rats were prevented by modified citrus pectin treatment, whereas Gal-3 blockade did not modify blood pressure levels. In the absence of blood pressure modifications, Gal-3 knockout mice were resistant to aldosterone-induced cardiac inflammation. In human cardiac fibroblasts, aldosterone increased Gal-3 expression via its mineralocorticoid receptor. Gal-3 and aldosterone enhanced proinflammatory and profibrotic markers, as well as metalloproteinase activities in human cardiac fibroblasts, effects that were not observed in Gal-3-silenced cells treated with aldosterone. In experimental hyperaldosteronism, the increase in Gal-3 expression was associated with cardiac inflammation and fibrosis, alterations that were prevented by Gal-3 blockade independently of blood pressure levels. These data suggest that Gal-3 could be a new molecular mechanism linking cardiac inflammation and fibrosis in situations with high-aldosterone levels, such as hypertension.</div></front></TEI><affiliations><list><country><li>Espagne</li><li>France</li></country><region><li>Grand Est</li><li>Lorraine (région)</li></region><settlement><li>Metz</li><li>Nancy</li></settlement><orgName><li>Université de Lorraine</li></orgName></list><tree><country name="France"><region name="Grand Est"><name sortKey="Martinez Martinez, Ernesto" sort="Martinez Martinez, Ernesto" uniqKey="Martinez Martinez E" first="Ernesto" last="Martínez-Martínez">Ernesto Martínez-Martínez</name></region><name sortKey="Cachofeiro, Victoria" sort="Cachofeiro, Victoria" uniqKey="Cachofeiro V" first="Victoria" last="Cachofeiro">Victoria Cachofeiro</name><name sortKey="Calvier, Laurent" sort="Calvier, Laurent" uniqKey="Calvier L" first="Laurent" last="Calvier">Laurent Calvier</name><name sortKey="Fernandez Celis, Amaya" sort="Fernandez Celis, Amaya" uniqKey="Fernandez Celis A" first="Amaya" last="Fernández-Celis">Amaya Fernández-Celis</name><name sortKey="Jaisser, Frederic" sort="Jaisser, Frederic" uniqKey="Jaisser F" first="Frederic" last="Jaisser">Frederic Jaisser</name><name sortKey="Jurado L Pez, Raquel" sort="Jurado L Pez, Raquel" uniqKey="Jurado L Pez R" first="Raquel" last="Jurado-L Pez">Raquel Jurado-L Pez</name><name sortKey="Rossignol, Patrick" sort="Rossignol, Patrick" uniqKey="Rossignol P" first="Patrick" last="Rossignol">Patrick Rossignol</name><name sortKey="Rossoni, Luciana V" sort="Rossoni, Luciana V" uniqKey="Rossoni L" first="Luciana V" last="Rossoni">Luciana V. Rossoni</name><name sortKey="Rousseau, Elodie" sort="Rousseau, Elodie" uniqKey="Rousseau E" first="Elodie" last="Rousseau">Elodie Rousseau</name><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name></country><country name="Espagne"><noRegion><name sortKey="L Pez Andres, Natalia" sort="L Pez Andres, Natalia" uniqKey="L Pez Andres N" first="Natalia" last="L Pez-Andrés">Natalia L Pez-Andrés</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000761 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000761 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26238446
|texte= Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26238446" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a InforLorV4
| This area was generated with Dilib version V0.6.33. |  |